

BOOK CHAPTERS

Marx G. Northern Area Health Service Clinical Handbook for Resident Medical Officers, 2000. Oncology Chapter.

Marx G, Yip S, Steer C, Harper P. Supportive Treatment in Gynaecologic cancers. In Chemotherapy for Gynecologic Neoplasms: Current Therapy and Novel Approaches. Edited by M. Penalver, R. Angioli, P. Benedetti-Panici, J. Kavanagh and S. Pecorelli. CRC Press. 1st Edition 2004 Peer Reviewed Journal Articles.

PEER REVIEWED AND JOURNALED ARTICLES

Sath Narayanan, Nicholas K. Ngui, Ben Kinchington, Joseph Do Woong Choi, Thomas Michael D. Hughes, Josie Rutovitz, Csilla Hasovits, Kazi J. Nahar, Senarath Edirimanne, **Gavin Marx.** Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early-stage breast cancer: An Australian institutional real-world experience. *Cancer Med.* 2024; 13:e7325. doi:[10.1002/cam4.7325](https://doi.org/10.1002/cam4.7325)

Howdle, G., Stephanou, A., Barrett, J., Roushdy, S., Ngui, N., Hughes, M., **Marx, G.** and Boyages, J. (2024), Has the COVID-19 pandemic resulted more advanced breast cancer? A hospital-based retrospective study. *ANZ Journal of Surgery.* <https://doi.org/10.1111/ans.19028>

Marx G, Chowdhury S, Krieger L, et al. A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia. *Asia-Pac J Clin Oncol.* 2024; 1-9.

Mahon KL, Sutherland SIM, Lin HM, Stockler M, Gurhey H, Mallesara G, Briscoe K, **Marx G,** et al. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. *The Prostate.* 2024;1-9. doi:[10.1002/pros.24691](https://doi.org/10.1002/pros.24691)

Mahfouz FM, Li T, Timmins HC, Horvath LG, Harrison M, Grimison P, **Marx G,** Goldstein D, Park SB. Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity. *J Natl Compr Canc Netw.* 2024 Feb 15:1-9. doi: 10.6004/jnccn.2023.7083. Epub ahead of print. PMID: 38364373.

Peter Grimison, Antony Mersiades, Adrienne Kirby, Annette Tognela, Ian Olver, Rachael L. Morton, Paul Haber, Anna Walsh, Yvonne Lee, Ehtesham Abdi, Stephen Della [1] Fiorentina, Morteza Aghmesheh, Peter Fox, Karen Briscoe, Jasotha Sanmugarajah, **Gavin Marx,** Ganessan Kichenadasse, Helen Wheeler, Matthew Chan, Jenny Shannon, Craig Gedye, Stephen Begbie, R. John Simes, Martin R Stockler. Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV): Final results of a randomized, placebo-controlled, phase 2/3 trial. *Journal of Clinical Oncology, accepted 18 Jan 2024.*

Mahfouz, F.M., Li, T., Joda, M. Harrison, M., Horvath L., Grimison P., King T., **Marx G., et al.** Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes. *Support Care Cancer* **32**, 46 (2024). <https://doi.org/10.1007/s00520-023-08245-w>

Vinod Ganju, **Gavin Marx,** Scott Pattison, Nancy B. Amaro-Mugridge, Jing Ting Zhao, Bryan R.G. Williams, Jennifer A. MacDiarmid, Himanshu Brahmhatt; Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells. *Clin Cancer Res* 2023.

Martin Harb, Arvind Kamath, **Gavin Marx,** Saurabh Gupta. Outcomes of endoscopic ultrasound-guided gastro-enterostomy for gastric outlet obstruction in a two-centre Australian Cohort (with video)}, *Asia-Pacific Journal of Clinical Oncology* 2023.

Sweeney C.J., Martin A.J., Stockler M.R., Begbie S., Cheung L., Chi K.N., Chowdhury S. Frydenberg M, Horvath L, Joshua A, Lawrence N, **Marx G** et al, ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. (2023) *The Lancet Oncology*, 24 (4), pp. 323-334.

Kirwin B, Saghaie T, Ing A, Hasovits C, **Marx G**. Cyclophosphamide induced Pneumonitis in patients receiving dose dense chemotherapy for early breast cancer. A case series and review of the literature. *Authorea Preprints*, 26 Apr 2023.

Chan A, Ruiz-Borrego M, **Marx G**, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JoséA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenás CH, Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, *The Breast* (2023), doi: <https://doi.org/10.1016/j.breast.2022.12.003>.

Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, Peter Button, Bianca Devitt, Benjamin C Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E Kiely, **Gavin Marx**, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter Gibbs. Pertuzumab study in the neoadjuvant setting for her2-positive non-metastatic breast cancer in Australia (persia) *International Journal of Cancer*. Cancer therapy and prevention. August 2022.

David Mizrahi, David Goldstein, Terry Trinh, Tiffany Li, Hannah C. Timmins, Michelle Harrison, **Gavin M. Marx**, Elizabeth J. Hovey, Craig R. Lewis, Michael Friedlander, Susanna B. Park. Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy. *Asia Pacific Journal of Clinical Oncology* 2022.

Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, **Marx GM**, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. *J Clin Oncol*. 2022 Mar 10;40(8):837-846. doi: 10.1200/JCO.21.00941. Epub 2021 Dec 20. PMID: 34928708.

Joseph Do Woong Choi, T. Michael D. Hughes, **Gavin Marx**, John Boyages, Josie Rutovitz, Csilla Hasovits, Andrew Parasyn, Senarath Edirimanne, Nicholas K. Ngui, "The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting", *The Breast Journal*, vol. 2022, ArticleID 1199245, 2022. <https://doi.org/10.1155/2022/1199245>

Christopher J. Sweeney, Andrew J. Martin, Martin R. Stockler, Stephen Begbie, Kim N. Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E. Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence, **Gavin M. Marx**, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy Parulekar, David W. Pook, M. Neil Reaume, Shahneen K. Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Emily Tu, Francisco Vera-Badillo, Scott G. Williams, Sonia Yip, Alison Y. Zhang, Robert R. Zielinski, Ian D. Davis, Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy, *European Urology*, Volume 80, Issue 3, 2021.

Hui-Ming Lin, Blossom Mak, Nicole Yeung, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate L. Mahon, Alison Zhang, Martin R. Stockler, Karen Briscoe, **Gavin Marx**, Megan Crumbaker, Phillip D. Stricker, Pan Du, Jianjun Yu, Shidong Jia, Tahlia Scheinberg, Michael Fitzpatrick, Paul Bonnitcha, David R. Sullivan, Anthony M. Joshua, Arun A. Azad, Lisa M. Butler, Peter J. Meikle, Lisa G. Horvath, Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase, *EBioMedicine*, Volume 72, 2021.

Christopher J. Sweeney Andrew J. Martin, Martin Stockler, Stephen Begbie Kim N. Chi^{li}, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E. Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence, **Gavin M Marx**, John McCaffery, Ray Mc Dermett, Margaret McJanett, Scott A. North, Francis Parnis, Ian D. Davis. Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. *European Oncology* May 2021

A. P. Barbour, E. T. Walpole, G. T. Mai, E. H. Barnes, D. I. Watson, S. P. Ackland, J. M. Martin, M. Burge, R. Finch, C. S. Karapetis, J. Shannon, L. M. Nott, S. Varma, **G. Marx**, G. L. Falk, V. GebSKI, M. Oostendorp, K. Wilson, J. Thomas, G. Lampe, J. R. ZalcbERG, J. Simes & B. M. Smithers, on behalf of the DOCTOR investigators. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial *Annals of Oncology*. Jan 2021.

Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, **Marx G**, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Saenz JG, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A, the CONTROL Study Investigators, Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial, *Annals of Oncology* (2020), doi: <https://doi.org/10.1016/j.annonc.2020.05.012>.

Hannah C. Timmins, Tiffany Li, Matthew C. Kiernan, Sally Baron-Hay, **Gavin Marx**, Frances Boyle, David Goldstein, Susanna B. Park. Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. *Supportive Care in Cancer* 2020.

Antonia Pearson, Andrew Booker, Martin Tio, **Gavin Marx**. Vaginal CO₂ laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. *Breast Cancer Research and Treatment*. 2019.

Choi JDW, Hughes TMD, **Marx G**, Rutovitz J Hasovits C, Ngui NK. Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experience. *Asia Pac J Clin Oncol*. 2019 Jun 19.

Ian D. Davis, Andrew J. Martin, , Martin R. Stockler, Stephen Begbie, Kim N. Chi, Simon Chowdhury, Xanthi Coskinas., Mark Frydenberg, Wendy E. Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence., **Gavin Marx**, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy Parulekar, David W. Pook, M. Neil Reaume, Shahneen K. Sandhu, Alvin Tan, T. Hsiang Tan, Alastair Thomson., Emily Tu, Francisco Vera-Badillo, Scott G. Williams, Sonia Yip, Alison Y. Zhang, Robert R. Zielinski, and Christopher J. Sweeney, for the ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group*. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *NEJM*, 2 June 2019.

Lok SW^{1,2}, De Boer R², Cordwell C³, **Marx G**⁴, Fox P⁵, Hasovits C⁴, Rutovitz J⁶, Harold M¹, Tran B^{1,2}, Wong HL^{1,2}, Gibbs P^{1,7} Demonstrating the feasibility of collecting secondary, de-identified data on Australian patients receiving treatment as part of a Medicine Access Program. *Intern Med J*. 2019 Feb 28.

EM Basch, M Scholz, JS de Bono, N Vogelzang, P. D Souza, **G Marx** et al Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain endpoint. *European Urology*, 2018

P Mainwaring, E Small, H Uemura, J Y Lee S-T Pang, **G Marx**, T G Kwon, T Satoh, A Bhaumik S Cheng. Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation. *Annals of Oncology*, Volume 29, Issue suppl_9, 1 November 2018.

L Chin-Lenn, R H De Boer, E Segelov, **G M Marx**, T M Hughes, N J McCarthy, S C White, S S Foo, J J Rutovitz, S Della-Fiorentina, R Jennens, Y C Antill, Tsoi, M F Cronk, J M Lombard, B E Kiely, J H Chirgwin, A Gorelik, G B Mann. The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable. *APJCO* Oct 2018.

Tan A, **Marx G**. Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia. *BMJ Case Reports* 2018; doi:10.1136/bcr-2017-22294.

Tan AC, Li BT, Nahar K, Danieletto S, Fong ES, Currer T, Parasyn A, Middleton P, Wong H, Smart D, Rutovitz JJ, McCloud P, Hughes TM, **Marx GM**. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. *Asia Pac J Clin Oncol*. 2018 Apr;14(2): e161-e166. doi: 10.1111/ajco.12779. Epub 2017 Sep 29.

Nahm N, Mee S, **Marx G**. Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review. *Asia Pac J Clin Oncol*. 2018;1-9.

JN Pulvers, **G Marx**. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review *Asia-Pacific Journal of Clinical Oncology*, 2017.

Hui-Ming Lin, Kate L Mahon, Calan Spielman, Howard Gurney, Girish Mallesara, Martin R Stockler, Patricia Bastick, Karen Briscoe, **Gavin Marx**, Alexander Swarbrick and Lisa G Horvath. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. *British Journal of Cancer* (2017) 116, 1002–1011. doi:10.1038/bjc.2017.50 www.bjcancer.com March 2017.

Thomas CL^{1,2}, Arasaratnam M³, Carlos G^{1,2,4}, Parasyn A⁵, Baumgart KW⁶, Fernandez-Penas P^{1,2,4}, **Marx G**^{2,3}. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib. *Australas J Dermatol.* 2017 Feb; 58(1):69-70.

R. T. Bergin, E. Hovey, A. Lloyd, **G. Marx**, P. Parente, T. Rapke, P. de Souza. Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. *Support Care Cancer* Sept 2017.

Bergin A, Hovey E, Lloyd A, **Marx G**, Parente P, Rapke T, De Souza P. Docetaxel-related fatigue in metastatic prostate cancer: a descriptive analysis. *Asia-Pacific Journal of Clinical Oncology* 12:52-52 August 2016.

Li, B., Barnes, T., Chan, D., Naidoo, J., Lee, A., Khasraw, M., **Marx, G.**, Kris, M., Clarke, S., Drilon, A., Pavlakis, N. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small cell lung cancers: A meta-analysis of randomized trials. *Lung Cancer*, 102, 21-27 2016.

Roger von Moos, Jean Jacques Body, Blair Egerdie, Alison Stopeck, Janet Brown, Lesley Fallowfield, Donald L. Patrick, Charles Cleeland, Danail Damyanov, Felipe Salvador Palazzo, **Gavin Marx**, Ying Zhou, Ada Braun, Arun Balakumaran, Yi Qian. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. *Supportive Care in Cancer*. March 2016.

Jennifer McClachlan, David L Chan, Megan A Crumbaker, **Gavin M Marx**. Neutrophil–lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer. *Cancer treatment communications* 2015.

R. Lakhanpal, J. Yoong, S. Joshi, D. Yip, L. Mileshkin, **G.M. Marx**, T. Dunlop, E.J. Hovey, S.A. Della Fiorentina, L. Venkateswaran, M.H.N. Tattersall, S. Liew, K. Field, N. Singhal, C.B. Steer. Geriatric assessment of older patients with cancer in Australia. A multicentre audit. *Journal of Geriatric Oncology*, 2015.

Kate Mahon, Hui-Ming Lin, Lesley Castillo, Brian Lee, Michelle Lee-Ng, Mark Chatfield, Karen Chiam, Samuel Breit, David Brown, **Gavin Marx**, Mark Molloy, Nick Pavlakis, Michael Boyer, Martin R Stockler, Roger J Daly, Susan Henshall, and Lisa Horvath. Cytokine profiling of docetaxel-resistant castration resistant prostate cancer. *BJC* 2015.

Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., **Marx, G.**, Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. *British Journal of Cancer*, 110(10), 2462-2471.

Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., **Marx, G.**, Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. *British Journal of Cancer*, 111(9), 1802-1809.

Smith, M., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., Tombal, B., Damiao, R., **Marx, G.**, Miller, K., et al (2013). Denosumab and Bone Metastasis-Free Survival in Men with Non-metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis by Baseline Prostate-Specific Antigen Doubling Time. *Journal of Clinical Oncology*, 31(30), 3800-3806.

von Moos, R., Body, J., Egerdie, B., Stopeck, A., Brown, J., Damyanov, D., Fallowfield, L., **Marx, G.**, Cleeland, C., Patrick, D., et al (2013). Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. *Supportive Care in Cancer*, 21(12), 3497-3507.

Won, A., Gurney, H., **Marx, G.**, de Souza, P., Patel, M. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. *BJU International*, 112(4), E250-E255.

Jennifer M McLachlan, **Gavin M Marx** and Margaret Bridgman. Severe symptomatic hypocalcaemia following a single dose of denosumab *Med J Aust* 2013; 199 (4): 242-243.

Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., **Marx, G.**, Cullen, M., Kerestes, Z., Pavlakis, N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. *Lung cancer* (Amsterdam, Netherlands). 75(2), 248-54. 2012.

Kao, S. C.-H., Hovey, E. and **Marx, G.** Second-line therapy for castrate-resistant prostate cancer: A literature review. *Asia-Pacific Journal of Clinical Oncology*, 7: 212–223. 2011.

Tebbutt, N, Murphy, F, Zannino, D, Wilson, K, Cummins, M, Abdi, E, Strickland, A, Lowenthal, R, **Marx, G**, Karapetis, C, Shannon, J, Goldstein, D, Nayagam, S, Blum, R, Chantrill, L, Simes, R, Price, T, Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. *Annals of Oncology*. 2011.

Christos S Karapetis, Kerry A Cheong, Desmond Yip, Andrew H Strickland, Christopher Steer, **Gavin Marx**, Sonia Yip, Kathryn Chrystal, Peter G Harper. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. *Asia-Pacific Journal of Clinical Oncology*. Volume 6, Issue 4, pages 298–305, December 2010.

Diana Adams and **Gavin Marx**. Daily Life as an Australian Medical Oncologist. *Journal of Oncology Practice*, Vol 6, No 3 (May), 2010: pp. 146-148.

C. B. Steer, **G. M. Marx**, N. Singhal, M. McJannett, D. Goldstein, R. Prowse. Cancer in older people: a tale of two disciplines. *Internal Medicine Journal*. Volume 39, Issue 11, Date: November 2009, 39(11) Pages: 771-775.

M. Khasraw¹, N. Pavlakis¹, S. McCowatt^{1,2}, C. Underhill³, S. Begbie⁴, P. de Souza⁵, A. Boyce⁶, F. Parnis⁷, V. Lim¹, R Harvie¹ and **G Marx**. Multicentre Phase I/II Study of PI-88, a Heparanase inhibitor in Combination with Docetaxel in Patients with Metastatic Castrate- Resistant Prostate Cancer. *Annals of Oncology*. Nov 2009.

Liangli Zhao¹, Brian Y. Lee¹, David A. Brown³, Mark P. Molloy⁴, **Gavin M. Marx**⁵, Nick Pavlakis⁵, Michael J. Boyer⁶, Martin R. Stockler⁶, Warren Kaplan², Samuel N. Breit³, Robert L. Sutherland¹, Susan M. Henshall¹ and Lisa G. Horvath Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. *Cancer Research* 69, 7696, October 1, 2009.

Pavlakis N, **Marx G**, White S, Lee CW, Khasraw M. Anti-angiogenic therapy for lung cancer (Protocol). *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD008047. DOI: 10.1002/14651858.CD008047.

Elizabeth Hovey¹, **Gavin Marx**², Andrew Kneebone³, Manish Patel⁴ and Jeremy Shapiro. An Australian Clinical Perspective: Management of Hormone Refractory (Androgen-Independent) Prostate Cancer. *Asia Pacific Journal of Oncology and Haematology* 2009.

Gavin M. Marx, Nick Pavlakis, Sally McCowatt, Stephen Begbie, Craig Underhill, Adam Boyce, David Bell, Phillip Katelaris, Rozelle Harvie, Chris Ward. A Phase II Trial of Docetaxel and Thalidomide in Patients with Metastatic Androgen Independent Prostate Cancer. The ProTaT Trial.

Rozelle Harvie MSc ^{1,2}, Florian Paturi ¹, Robyn Taylor BAppSci ², Ross Davey PhD^{1,2}, Rick Abraham³, **Gavin Marx**², Martin Cullen², Zoltan Kerestes PhD ^{1,2}, and Nick Pavlakis^{1,2}. The predictive role of serum VEGF in an advanced malignant mesothelioma (MM) patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.

M. Khasraw and **Gavin Marx**. Chemotherapy in the elderly. *Cancer Forum*. Mar 2008. Vol 32 Issue 1.

Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., **Marx, G.**, Smith, G. The utility of FDG-PET in the preoperative staging of esophageal cancer. *Diseases of the Esophagus*. 2008; 21:389-394.

Steer CB, Chrystal K, Choong KA, Galani E, **Marx GM**, Strickland A, Yip D, Lofts F, Gallagher C, Thomas H, Harper PG. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. *Gynecol Oncol*. 2006 Nov; 103(2):439-45. Epub 2006 Apr 27.

G. M. Marx, C. B. Steer, and P. G. Harper. Reply to the letter "Limitations of bedside estimates of renal function", by M. J. Dooley and S. G. Poole *Ann Oncol* 2005 16: 990.

Marx G, Taylor J, Goldstein D. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. *Intern Med J*. 2005 Jan; 35(1):34-8.

Gavin M. Marx and Josie J. Rutovitz. Commentary on Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxy] Ethanamine (BMS-2173801-01) Combined with Doxorubicin versus Doxorubicin alone in metastatic/ recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19. *Women's Oncology Review* 2004; 4:133-134.

E. Galani, **GM. Marx**, CB Steer, PG Harper Pseudomyxoma peritonei. "The controversial disease". *Int J Gynaecol. Oncol*. 2003 Jul-Aug; 13(4):413-8. Review.

Ring A, **Marx G**, Steer C, Prendiville J, Ellis P. Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. *Int J Clin Pract*. 2003 Jul-Aug; 57(6):542-3.

Ng T, Marx G, Littlewood T, Macdougall I. Recombinant Erythropoietin in clinical practice. *Post Graduate Medical Journal*. 79: 367-376, 2003.

Marx G, Harper PG. Non-platinum-based chemotherapy in the treatment of Non-Small Cell Lung Cancer. *Lung Cancer*. 2002 Nov; 38 Suppl 2: S51-4. Review.

GM Marx, GM Blake, E Galani, CB Steer, SE Harper, KL Adamson, DL Bailey, PG Harper. Evaluation of the Cockcroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. *Annals of Oncology*. *Ann Oncol*. 2004 Feb 15 (2):291-5.

Ring A, **Marx GM**, Steer CB, Harper PG. Influenza vaccination and chemotherapy. A shot in the dark? *Journal of supportive care in cancer*. Sept 2002. 10 (6). 462-5.

Marx G and Harper PG. Combined modality treatments in early non-small cell lung cancer. IASLC meeting. *Lung Cancer*. October 2002. 38 (1). S23-S25.

Marx G and Harper P. Non-Platinum gemcitabine combinations in non-small cell lung cancer. *Lung Cancer*. 38 (2002) S51-S54.

Marx G, Lewis C, Hall K, Levi J, Ackland S. A Phase 1 study of Docetaxel and Ifosfamide in the treatment of advanced cancer. *British Journal of Cancer*. 2002. Oct 7. 87(8), 846-9.

Steer CB, **Marx GM**, Galani E, Harper PG, Khayat D. Quality of life: It's never too late. *Journal of Clinical Oncology*. Jul 1, 2002, 2915-2917.

Marx GM, S McCowatt, JA Levi, DR Bell, F Boyle, N Pavlakis, R Freilich, R Cook, M Biggs, N Little, HR Wheeler. Phase II study of Thalidomide as an Anti-Angiogenic agent in the treatment of Recurrent Glioblastoma Multiforme. *Journal of neuro-oncology*. Aug 2001; 54(1): 31-38.

Steer CB, **Marx GM**, Harper PG. Is there Quality in clinical benefit? *Annals of Oncology*. 2001; 12(9): 1191-3.

Marx G, Pavlakis N, Steer C, Harper P, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations-Time to take stock! *JCO editorial*. Mar 15 2002, 1446-1448.

Marx G, Goldstein D. Elevated Alpha foetoprotein and hepatic metastases-is not always what it seems! *Annals of Oncology*. 13:167-169, 2002.

Marx G, Friedlander M, Hacker N. Cytotoxic drug treatment of vaginal and vulval cancer. *CME Journal of gynecologic oncology*. 2001 18(2).

Marx G, Friedlander M. Drug toxicity: Prevention and management. CME Journal of gynecologic oncology. 2001 18(2).

CB Steer, **GM Marx**. Quality of life issues in elderly patients with cancer. Geriatric Medicine. October 2001: 23-25.

GM Marx, A Ring, CB Steer, PG Harper. Quality of life - It's not just PR.
http://www.skila.com/mir/rtkmir04_sep2001.shtml.

Harris R, **Marx G**, Kark A, Liddle C, Gillett M. Colchicine Induced Bone Marrow Suppression: Treatment with Granulocyte Colony Stimulating Factor- J of Emergency Medicine. vol 18(4) May 2000.

Ring A, **Marx GM**, Steer CB, Harper PG. Flu vaccination and Chemotherapy. A cancer centre's experience.

CLINICAL TRIALS AS PRINCIPAL INVESTIGATOR

Trial Name	Protocol Title
ABC	A phase 11 trial of gemcitabine in fixed dose rate infusion combined with cisplatin in patients with inoperable biliary tract carcinomas
Abiraterone EAP	An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
IBIS 2	An international multi-centre trial of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer and tamoxifen vs anastrozole in postmenopausal women with hormone sensitive DCIS
Millenium	A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has progressed During or Following Docetaxel-based Therapy
Alimta	Randomised, phase III trial of Alimta + Cisplatin Vs Gemcitabine + Cisplatin in patients with locally advanced metastatic NSCLC
MIC 1	Phase II Study to Investigate the Ability of Macrophage Inhibitory Cytokine-1 (MIC-1)
Amgen 249	A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination with Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Amgen 611	A Phase 1b/II Study to Assess the Safety and Efficacy of AMG102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer
Amgen201	A phase 3 multi centre, randomised, placebo-controlled, double-blind trial of AMG706 in combination with Paclitaxel and Carboplatin for advanced NSCLC

Amgen244	A randomised, double-blind, multicenter study of denosumab compared with zoledronic acid (zometa) in the treatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
Armor 3	A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared with Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA Metastatic Castrate Resistant Prostate Cancer -ARMOR3
Ascent	An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin™) ASCENT
ASPECCT	A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
ATLAS	A large simple randomised study to assess the efficacy and safety of prolonged tamoxifen treatment for women with a history of breast cancer
AvaGast	A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with advanced gastric cancer
Averel	A randomised, open-label, multicentre study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab/docetaxel or in combination with trastuzumab alone in first line treatment for patients with HER2 positive locally advanced or metastatic breast cancer
Challenge	A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: a randomised controlled trial (CHALLENGE)
Meteor	A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Plato	A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
BMS CA184-437	Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects with Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

BNIT - Prospect	A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
Bolero 6	Three arm randomised, open label phase 2 study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with oestrogen receptor positive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole
Bosentan	A multicentre, randomised, double-blind, placebo-controlled phase II study to evaluate the effect of bosentan in patients with stage IV metastatic melanoma treated with Dacarbazine
Cabazitaxel EAP	Multicentre, single-arm, open label, clinical study intended to provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen and to document safety of cabazitaxel in these patients
Prosper	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Cetuximab	Phase II study of cetuximab + BSC vs BSC alone
Enzamet	Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer
CILAB	Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
CO20	A Phase 3 randomised study of Brivanib alaninate in combination with Cetuximab (erbitux) versus placebo in combination with Cetuximab (Erbix) in patients previously treated with combination chemotherapy for metastatic colorectal cancer
CO23	A phase III randomised study of BB1608 and best supportive care versus placebo and best supportive care in patients with pretreated advanced colorectal carcinoma
P3BEP	Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor risk met germ cell tumours
Comet 1	A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100

Comet 2	A Phase 3, randomised, double-blind, placebo-controlled study of Cabozantinib (XL184) vs. mitoxantone plus prednisone in med with previously treated symptomatic castration-resistant prostate cancer - XL184-306
Doctor	A Randomised phase 2 trial of pre op Cisplat, 5FU and Docetaxel +/- radiotherapy based on poor early response to standard chemo for resectable adenocarcinoma of the esophagus and or OG junction
COTEZO	A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal adenocarcinoma
Cougar 301	A phase 3, randomised, double-blind, placebo-controlled study of abiraterone acetate (CB7630) plus prednisone in patients with metastatic castration-resistant prostate cancer who have failed docetaxel-based chemotherapy
Cougar 302	A phase 3, randomised, double-blind, placebo-controlled study of Abiraterone Acetate (CB7630) plus Prednisone in Asymptomatic Castration-Resistant Prostate Cancer
D Care	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
Denosumab-103	A randomised, double-blind, multicentre study of denosumab compared with zoledronic acid (zometa) in the treatment of bone metastases in men with hormone-refractory prostate cancer
Denosumab-136	A randomised, double-blind, multicentre study of denosumab compared with zoledronic acid (zometa) in the treatment of bone metastases in subjects with advanced breast cancer
Denosumab-147	A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study of Denosumab on Prolonging Bone Metastasis – Free Survival in Men with Hormone Refractory Prostate Cancer
BCG-MMC	Adding Mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: A randomized phase 3 trial “(BCG + MMC Trial)”
Spartan	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (SPARTAN)

Enthuse-14	A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who Pain Free or Mildly Symptomatic.
Enthuse-15	A phase III, randomised, placebo-controlled, double-blind study to assess the efficacy and safety of once-daily orally administered ZD4054 10mg in non-metastatic hormone-resistant prostate cancer patients
Monarch 3	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting
Embark	A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men with High Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
ACIS	A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Gilead	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
GILEAD 2013	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
GU09-145	Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
HELOISE	A randomised, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/capecitabine chemotherapy, as first-line therapy in patients with HER2-positive metastatic gastric or gastro-oesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease
LAAVA	Laser therapy for vulvovaginal atrophy symptoms in breast cancer patients (LAAVA)

Horizon 2	A randomised, double-blind, phase III study to compare the efficacy and safety of AZD2171 when added to 5-fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) with the efficacy and safety of placebo when added to FOLFOX or XELOX in patients with previously untreated metastatic colorectal cancer
Horizon 3	A randomised, double-blind, multi-centre phase II/III study to compare the efficacy of Cediranib (Recentin, AZD2171) in combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the efficacy of Bevacizumab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer
Ibandronate	Comparative study of the efficacy of oral Ibandronate vs Zometa with respect to changes in biochemical markers of bone turnover with metastatic disease due to breast cancer
Puma-6201	An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
Ignite	A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma histologies: The IGNITE study
Solar 1	A phase III randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment
INVITE	Randomised, open label, parallel group, multicentre phase II study of PFS comparing Iressa 250mg tablets vs Vinorelbine 30mg/m ² infusion in chemo-naïve, elderly patient with locally advanced stage IIIB/metastatic (Stage IV) NSCLC
IRESSA	Double-blind placebo controlled randomised phase 3 trial of Iressa + BSC vs placebo + BSC
Keynote 676	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction

IMpower132	A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination with Carboplatin or Cisplatin+Pemetrexed Compared with Carboplatin or Cisplatin+Pemetrexed in Patients Who Are Chemotherapy-Naïve and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
LUX	An open-label, randomized phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment
Mark	A phase II, Biomarker Identification Trial for Erlotinib (Tarceva) in patients with advanced pancreatic carcinoma. (MARK)
MAX	A randomised phase II/III study to evaluate the role of mitomycin C, avastin and xeloda in patients with metastatic colorectal cancer
Keynote-199	Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)
Metric	A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
GALAHAD	A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration Resistant Prostate Cancer and DNA-Repair Anomalies
MOTIF	A Prospective, randomised, double-blind, placebo-controlled Phase III study of Modafinil to improve fatigue and quality of life in patients treated with Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer
Neoplasnet	Phase I, open-label trial to determine safety, efficacy of neoplasnet in patients with Stage IV cancer who have exhausted all other forms of conventional therapies
NET	A programme to assess the long-term safety and efficacy of Somatuline® Autogel® in the treatment of NET when administered at home or by a healthcare professional
HERO	HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
CanStem111P	A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
AGEN-1884	A Phase IIa Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with Pembrolizumab in Subjects with Chemotherapy Naïve, PD-L1 high metastatic Non-Small Cell Lung Cancer

Panitumumab	A Randomised, Multicentre Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal Cancer
Peggy	A Phase II, Randomized Study of Paclitaxel with GDC-0941 Versus Paclitaxel with Placebo in Patients with Locally Recurrent or Metastatic Breast Cancer
Prevail	Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Metastatic Prostate Cancer Who Have Failed on Androgen Deprivation Therapy and Have Not Received Previous Chemotherapy
PROGEN	Phase II study of Taxotere + PI-88 in advanced NSCLC
PROPIT	A randomised phase II study of two dose schedules of PI-88 in combination with docetaxel in patients with androgen-independent prostate cancer
Proselica	Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m ² and at 25 mg/m ² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated with a Docetaxel-Containing Regimen
Persia	Pertuzumab Study in the Neoadjuvant setting for Her2-Positive Non-Metastatic Breast Cancer in Australia (PeRSIA)
PROTAT	A feasibility efficacy study of taxotere + prednisone +thalidomide in HRPC.1st line taxotere/ thalidomide
Puma-Nala	A study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with her2+ metastatic breast cancer who have received two or more prior her2-directed regimens in the metastatic setting (NALA)
Rachel	A phase II, Dose-Escalation to Rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients with Metastatic Pancreatic Cancer." (Rachel)
Ready	A Randomised Double-blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer
Register	A Multicentre Phase II Study of Risk Evaluation in GIST with Selective Therapy Escalation for Response ("The Study")

RIBBON 1	A multicenter, phase 3, randomised, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer
RIBBON 2	A phase III, multicentre, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer
Sail	Open label study of Avastin in combination with platinum containing chemotherapy as first line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer
SCOTROC-4	A prospective, multicentre, randomised trial of carboplatin flat dosing vs intrapatient dose escalation in first line chemotherapy of ovarian, fallopian tube and primary peritoneal cancers
Nivorad	A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first- or second-line chemotherapy
Sirflox	Randomised comparative study of Folfox6m plus sir – spheres versus Folfox6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma. (SIRFLOX)
LAAVA 2	Laser Therapy for vulvovaginal symptoms in breast cancer patients (LAAVA 2)
Biosceptre BIL06v-101	A Phase 1 Study to Evaluate the Safety, Tolerability, Immunogenicity and Anti-Tumour Activity of BIL06v/Alhydrogel® in Patients with Advanced Solid Tumours
Stone Bleo	The role of the insulin-like growth factor family in pulmonary disease: bleomycin and pulmonary toxicity
SUGEN	A phase III randomised study of SUO11248 vs Interferon alpha 1st line systemic treatment for patients with metastatic renal cell carcinoma
Sutent (Sun)	A multicenter, randomised, double-blind, phase 3 study of Sunitinib plus prednisone versus prednisone in patients with progressive Metastatic hormone-refractory prostate cancer after failure of a Docetaxel-based chemotherapy regimen
Tax/Gem	Randomized comparison of first line Docetaxel/Gemcitabine doublet chemotherapy versus sequential single agent chemotherapy (Docetaxel followed by Gemcitabine) in stage 111B/1V NSCLC

VELOUR	A Multinational, Randomised, Double-Blind Study, Comparing the Efficacy of Aflibercept once every 2 weeks in patients with Metastatic Colorectal Cancer (MCRC) treated with Irinotecan / 5-FU combination (FOLFIRI) after failure of an Oxaliplatin based regimen
VENICE	A multicentre, randomised, double-blind study comparing the efficacy and safety of Aflibercept versus placebo administered every 3 weeks in patients treated with docetaxel / prednisone for metastatic androgen-independent prostate cancer
Vinflunine	A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
AZTEC	A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced Triple negative breast Cancer
Zactima/Tarceva	A phase III, randomised, double-blind, multi-centre parallel-group study to assess the efficacy of ZD6474 (ZACTIMA) versus Erlotinib (TARCEVA) in patients with locally advanced or metastatic (Stage IIIB-IV) non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy
Zest	A double-blind, placebo-controlled trial of Zolof's effects on symptoms and survival time in advanced cancer
Fight	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric or Gastroesophageal Cancer
Solstice	An open-label, randomised, phase III Study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy - SOLSTICE study
Winpro	A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer
Natalee	A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant Trial with Ribociclib [LEE011]: NATALEE)
Carolyn	A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying α -galactosyl ceramide (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate

Magnitude	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
FORT-1	A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy
Duloxetine INFOCUS	The use of Duloxetine for the treatment of chemotherapy-induced peripheral neuropathy
Allvascular	Phase Ib/II Study of Intra-Arterial Liver Isolation Chemotherapy in Patients with Hepatic Metastases from Colorectal Cancer
Contessa 2	A Multinational, Multicenter, Phase 2 Study of Tese taxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane (CONTESSA 2)
GSK - 204697	A phase IB open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC)
BMS CA209-650	A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
Leep	A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer
Ameera	Study to determine whether Amcenestrant (SAR439859) in combination with palbociclib improves progression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease
NEO-N	A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early-stage triple negative breast cancers
CHECKMATE 7DX	A Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)
CHECKMATE 7DX	A Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
PREVALENCE	